10207 Results

People

  1. Gonen
    Gonen
  2. Vickers
    Vickers
  3. Panageas
    Panageas
  4. Patil
    Patil
  5. Schultz
    Schultz
  6. Giralt
    Giralt
  7. Zhang
    Zhang
  8. Jarnagin
    Jarnagin
  9. Heller
    Heller
  10. D'Angelica
    D'Angelica

Groups

  1. Epidemiology and Biostatistics (10207)
  2. Biostatistics Service (6564)
  3. Department of Medicine (4907)
  4. Population Sciences Research Program (4867)
  5. Surgery (3680)
  6. Survivorship Research (3597)
  7. Solid Tumor Oncology Division (3294)
  8. GSK Faculty (2807)
  9. Center for Pancreatic Cancer Research (2495)
  10. Health Outcomes Research Group (2069)
  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (6429)
  2. Meeting Abstract (3245)
  3. Editorial (116)
  4. Review (93)
  5. Research Letter (80)
  6. Correspondence (77)
  7. Conference Paper (54)
  8. Miscellaneous (52)
  9. Book Section (43)
  10. Guidelines (13)
  11. Book Whole (5)
Groups
  1. Epidemiology and Biostatistics (10207)
  2. Biostatistics Service (6564)
  3. Department of Medicine (4907)
  4. Population Sciences Research Program (4867)
  5. Surgery (3680)
  6. Survivorship Research (3597)

More Groups

People
  1. Mithat Gonen (1028)
  2. Andrew Vickers (880)
  3. Sean Devlin (601)
  4. Katherine Panageas (512)
  5. Sujata Patil (511)
  6. Nikolaus Schultz (486)

More People

Years
  1. 2025 (209)
  2. 2024 (622)
  3. 2023 (692)
  4. 2022 (732)
  5. 2021 (610)
  6. 2020 (625)

More Years

Publications
  1. Journal of Clinical Oncology (1374)
  2. Blood (534)
  3. Annals of Surgical Oncology (462)
  4. Cancer Research (274)
  5. International Journal of Radiation Oncology, Biology, Physics (258)
  6. Clinical Cancer Research (250)

More Publications

Publishers
  1. American Society of Clinical Oncology (1487)
  2. Elsevier Inc. (1206)
  3. Springer (925)
  4. American Association for Cancer Research (761)
  5. Elsevier Science, Inc. (685)
  6. American Society of Hematology (601)

More Publishers

Results (10207)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profiles in patients receiving CD19-CAR T-cell therapy for B-cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Parascondola, A.; Saldia, A.; Imber, B. S.; Tomas, A. A.; Landego, I.; Lin, R. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies
    Meeting Abstract

    Shahid, S.; Flynn, G. C.; Mauguen, A.; Bieler, J.; Prockop, S. E.; Scaradavou, A.; Boelens, J. J.; Sauter, C. S.; Perales, M. A.; Giralt, S. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluation of the impact of tocilizumab use in recipients of CAR T cells for non-Hodgkin lymphoma
    Meeting Abstract

    Cassanello, G.; Luttwak, E.; Devlin, S. M.; Luna De Abia, A.; Corona, M.; Landego, I.; Parascondola, A.; Saldia, A.; Tomas, A. A.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Enhancing myeloid cancer genomic profiling through comprehensive whole genome sequencing using the Isabl GxT Heme analytical platform
    Meeting Abstract

    Deshpande, A. S.; Levine, M. F.; Hadi, K.; Gundem, G.; Patel, M.; Skrzypczak, S.; Kung, A. L.; Medina-Martínez, J. S.; Papaemmanuil, E.
    Blood (2023)

    Fulltext@MSK | Save
  • Pilot study of longitudinal geriatric assessment and neurocognitive evaluation in CAR T-cell therapy for older patients with relapsed refractory, large B-cell lymphoma
    Meeting Abstract

    Lin, R. J.; Kim, S. J.; Correa, D.; Elko, T. A.; Lobaugh, S.; Baser, R.; Koch, A.; Hanley, D. M.; Palomba, M. L.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Single cell whole genome measurement of genomic heterogeneity and clonal evolution in multiple myeloma
    Meeting Abstract

    McPherson, A.; Maclachlan, K. H.; Myers, M.; Satas, G.; Landgren, O.; Usmani, S. Z.; Shah, S. P.; Maura, F.
    Blood (2023)

    Fulltext@MSK | Save